Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis

Immune checkpoint inhibitors (CPIs) are a relatively newly licenced cancer treatment, which make a once previously untreatable disease now amenable to a potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone to off-target immune-mediated tissue injury,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Jonathan W., Cozzetto, Domenico, Alexander, James L., Danckert, Nathan P., Madgwick, Matthew, Knox, Naomi, Sieh, Jillian Yong Xin, Olbei, Marton, Liu, Zhigang, Ibraheim, Hajir, Blanco, Jesus Miguens, Kudo, Hiromi, Seoane, Rocio Castro, Possamai, Lucia A., Goldin, Robert, Marchesi, Julian, Korcsmaros, Tamas, Lord, Graham M., Powell, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593820/
https://www.ncbi.nlm.nih.gov/pubmed/37872166
http://dx.doi.org/10.1038/s41467-023-41798-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593820/
https://www.ncbi.nlm.nih.gov/pubmed/37872166
http://dx.doi.org/10.1038/s41467-023-41798-2

Ejemplares similares